{
    "nctId": "NCT02677714",
    "briefTitle": "99mTc-rhAnnexin V-128 Imaging and Cardiotoxicity in Patients With Early Breast Cancer",
    "officialTitle": "99mTc-rhAnnexin V-128 Imaging of Apoptosis and Cardiotoxicity in Relationship to Ventricular Function in Patients With Early Stage Breast Cancer Receiving Doxorubicin-Based Chemotherapy",
    "overallStatus": "TERMINATED",
    "conditions": "Breast Cancer, Doxorubicin Induced Cardiomyopathy",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "NA",
    "primaryPurpose": "DIAGNOSTIC",
    "enrollmentCount": 14,
    "primaryOutcomeMeasure": "Part I / Proof of Concept (PoC): Number of Participants Evaluated for Imaging Feasibility",
    "eligibilityCriteria": "Inclusion criteria:\n\n1. Females \\>= 18 years of age with histologically confirmed early stage (Stage I, II or III) HER-2 negative breast cancer and planned for (neo)adjuvant doxorubicin-based chemotherapy (AC every 2 or 3 weeks x 4 cycles)\n2. Eastern Cooperative Oncology Group Status (ECOG) \u2264 2\n3. Able and willing to comply with the study procedures\n\nExclusion criteria:\n\n1. Pregnancy or lactation\n2. Moderate or severe valvular stenosis or regurgitation\n3. History of atrial fibrillation or flutter\n4. History of any disease or relevant physical or psychiatric condition which may interfere with the study objectives at the investigator judgment\n5. Know hypersensitivity to the investigational product (IP) or any of its components\n6. Prosthetic valve or pacemaker\n7. Claustrophobia or inability to lie still in a supine position\n8. Contraindication(s) to the CMRI procedure\n9. Participation in another clinical trial within 4 weeks before study inclusion, except for patients who have participated or who are currently participating in a study without any study drug administration\n10. Unwillingness to provide consent",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}